Cargando…
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine strategies. Although vaccination strategies repr...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131930/ https://www.ncbi.nlm.nih.gov/pubmed/15860133 http://dx.doi.org/10.1186/1479-5876-3-17 |
_version_ | 1782123962228015104 |
---|---|
author | Yee, Cassian |
author_facet | Yee, Cassian |
author_sort | Yee, Cassian |
collection | PubMed |
description | Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine strategies. Although vaccination strategies represent more readily available reagents, adoptive T cell therapy provides highly selected T cells of defined phenotype, specificity and function that may influence their biological behavior in vivo. Adoptive T cell therapy offers not only translational opportunities but also a means to address fundamental issues in the evolving field of cancer immunotherapy. |
format | Text |
id | pubmed-1131930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-11319302005-05-20 Adoptive T cell therapy: Addressing challenges in cancer immunotherapy Yee, Cassian J Transl Med Review Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine strategies. Although vaccination strategies represent more readily available reagents, adoptive T cell therapy provides highly selected T cells of defined phenotype, specificity and function that may influence their biological behavior in vivo. Adoptive T cell therapy offers not only translational opportunities but also a means to address fundamental issues in the evolving field of cancer immunotherapy. BioMed Central 2005-04-28 /pmc/articles/PMC1131930/ /pubmed/15860133 http://dx.doi.org/10.1186/1479-5876-3-17 Text en Copyright © 2005 Yee; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Yee, Cassian Adoptive T cell therapy: Addressing challenges in cancer immunotherapy |
title | Adoptive T cell therapy: Addressing challenges in cancer immunotherapy |
title_full | Adoptive T cell therapy: Addressing challenges in cancer immunotherapy |
title_fullStr | Adoptive T cell therapy: Addressing challenges in cancer immunotherapy |
title_full_unstemmed | Adoptive T cell therapy: Addressing challenges in cancer immunotherapy |
title_short | Adoptive T cell therapy: Addressing challenges in cancer immunotherapy |
title_sort | adoptive t cell therapy: addressing challenges in cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131930/ https://www.ncbi.nlm.nih.gov/pubmed/15860133 http://dx.doi.org/10.1186/1479-5876-3-17 |
work_keys_str_mv | AT yeecassian adoptivetcelltherapyaddressingchallengesincancerimmunotherapy |